Search results
Showing 226 to 240 of 262 results for carcinoma
Belzutifan for previously treated advanced renal cell carcinoma [ID6154]
Discontinued Reference number: GID-TA11086
NICE has developed a medtech innovation briefing (MIB) on ADXBLADDER for detecting bladder cancer .
NICE has developed a medtech innovation briefing (MIB) on Paige Prostate for prostate cancer .
NICE has developed a medtech innovation briefing (MIB) on the ATEC breast biopsy system
Nivolumab with ipilimumab for untreated advanced renal cell carcinoma (TA581)
This guidance has been updated and replaced by NICE technology appraisal guidance 780.
Avelumab with axitinib for untreated advanced renal cell carcinoma (TA645)
This guidance has been updated and replaced by NICE technology appraisal guidance 1120.
Nivolumab for adjuvant treatment of localised renal cell carcinoma [ID6362]
Discontinued Reference number: GID-TA11421
Evidence-based recommendations on dostarlimab (Jemperli) for treating advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency in adults who have had platinum-based chemotherapy.
Evidence-based recommendations on denosumab (XGEVA) for the prevention of skeletal-related events in adults with bone metastases from solid tumours.
Cabozantinib for previously treated advanced hepatocellular carcinoma (terminated appraisal) (TA582)
This guidance has been updated and replaced by NICE technology appraisal guidance 849.
Endoscopic full thickness removal of non-lifting colonic polyps (HTG439)
Evidence-based recommendations on endoscopic full thickness removal of non-lifting colonic polyps. This involves using a special device to remove the polyp and seal the bowel wall closed afterwards.
View recommendations for HTG439Show all sections
Everolimus for the second-line treatment of advanced renal cell carcinoma (TA219)
This guidance has been updated and replaced by NICE technology appraisal guidance 432.
In development Reference number: GID-TA11008 Expected publication date: TBC
Evidence-based recommendations on cabozantinib (Cabometyx) for previously treated advanced differentiated thyroid cancer unsuitable for or refractory to radioactive iodine, in adults.
Evidence-based recommendations on pembrolizumab (Keytruda) with carboplatin and paclitaxel for adults with untreated metastatic squamous non-small-cell lung cancer.